Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma
Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma
About this item
Full title
Author / Creator
Publisher
London, England: SAGE Publications
Journal title
Language
English
Formats
Publication information
Publisher
London, England: SAGE Publications
Subjects
More information
Scope and Contents
Contents
Temsirolimus is an inhibitor of the mammalian target of rapamycin (mTOR) kinase, a protein that has been shown to be particularly active in metastatic renal cell carcinoma (mRCC) with poor prognosis. Therefore, temsirolimus should be considered as the first-line treatment indicated in mRCC patients classified as poor risk. The benefits of temsiroli...
Alternative Titles
Full title
Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_14eef5fc218b4a62803295a88225d02f
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_14eef5fc218b4a62803295a88225d02f
Other Identifiers
ISSN
1756-2872
E-ISSN
1756-2880
DOI
10.1177/1756287215574457
